{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:55:21Z","timestamp":1772826921432,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40273-018-0675-9","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T20:47:41Z","timestamp":1527194861000},"page":"1015-1027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK"],"prefix":"10.1007","volume":"36","author":[{"given":"Paul","family":"Emery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolijn","family":"Van Keep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Beard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LaStella","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen Marc","family":"Jugl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"issue":"7568","key":"675_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","volume":"333","author":"CM McVeigh","year":"2006","unstructured":"McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ (Clin Res Ed). 2006;333(7568):581\u20135. \n                    https:\/\/doi.org\/10.1136\/bmj.38954.689583.DE\n                    \n                  .","journal-title":"BMJ (Clin Res Ed)"},{"key":"675_CR2","volume-title":"Ankylosing spondylitis (AS) guidebook","author":"National Ankylosing Spondylitis Society","year":"2012","unstructured":"National Ankylosing Spondylitis Society. Ankylosing spondylitis (AS) guidebook. London: National Ankylosing Spondylitis Society; 2012."},{"issue":"11","key":"675_CR3","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921\u20135. \n                    https:\/\/doi.org\/10.1136\/ard.2011.151191\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"675_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/rheumatology\/kew223","volume":"56","author":"L Hamilton","year":"2017","unstructured":"Hamilton L, Barkham N, Bhalla A, Brittain R, Cook D, Jones G, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology (Oxf, Engl). 2017;56(2):313\u20136. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew223\n                    \n                  .","journal-title":"Rheumatology (Oxf, Engl)"},{"key":"675_CR5","volume-title":"TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). Technology Appraisal Guidance","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383). Technology Appraisal Guidance. London: National Institute for Health and Care Excellence; 2016."},{"key":"675_CR6","volume-title":"Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407). Technology Appraisal Guidance","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407). Technology Appraisal Guidance. London: National Institute for Health and Care Excellence; 2016."},{"key":"675_CR7","unstructured":"Scottish Medicines Consortium. Advice ID 1159\/16: secukinumab (Cosentyx). \n                    https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1159_16_secukinumab_Cosentyx_AS\/secukinumab_Cosentyx\n                    \n                  . Accessed 20 Sept 2017."},{"issue":"26","key":"675_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1505066\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"675_CR9","doi-asserted-by":"publisher","unstructured":"Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, et al. Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess (Winch, Engl). 2016;20(9):1\u2013334, v\u2013vi. \n                    https:\/\/doi.org\/10.3310\/hta20090\n                    \n                  .","DOI":"10.3310\/hta20090"},{"key":"675_CR10","volume-title":"Week 12 BASDAI 50 response predicts long-term efficacy of secukinumab in patients with active ankylosing spondylitis independent of previous TNFi exposure","year":"2017","unstructured":"Emery P, Halliday A, Jugl S, Mokashi S, Porter B, Martin R, et al., editors. Week 12 BASDAI 50 response predicts long-term efficacy of secukinumab in patients with active ankylosing spondylitis independent of previous TNFi exposure. Birmingham: British Society for Rheumatology; 2017."},{"issue":"6","key":"675_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landewe","year":"2009","unstructured":"Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863\u20137. \n                    https:\/\/doi.org\/10.1136\/ard.2008.091793\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"675_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12\u00a0year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52\u20139. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204055\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"675_CR13","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354. \n                    https:\/\/doi.org\/10.1002\/art.38070\n                    \n                  .","journal-title":"Arthritis Rheum"},{"key":"675_CR14","unstructured":"Baeten D, Braun J, Sieper J, Dougados M, Deodhar AA, Baraliakos X, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 2015;67(suppl 10)."},{"key":"675_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd008794.pub2","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011. \n                    https:\/\/doi.org\/10.1002\/14651858.cd008794.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"key":"675_CR16","unstructured":"European Medicines Agency (EMA). Cosentyx: EPAR\u2014product information. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac058001d124\n                    \n                  . Accessed 4 Jun 2017."},{"key":"675_CR17","unstructured":"Office for National Statistics. National life tables: United Kingdom (2011\u20132013). \n                    https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables\n                    \n                  . Accessed 23 May 2017."},{"key":"675_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). PMG9: guide to the methods of technology appraisal\u2014the reference case (2013). \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case\n                    \n                  . Accessed 23 May 2017."},{"issue":"2","key":"675_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1017\/s0266462308080203","volume":"24","author":"MF Drummond","year":"2008","unstructured":"Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? Int J Technol Assess Health Care. 2008;24(2):146\u201350. \n                    https:\/\/doi.org\/10.1017\/s0266462308080203\n                    \n                  .","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"675_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/rheumatology\/keh669","volume":"44","author":"A Keat","year":"2005","unstructured":"Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a Working Party of the British Society for Rheumatology. Rheumatology (Oxf, Engl). 2005;44(7):939\u201347. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keh669\n                    \n                  .","journal-title":"Rheumatology (Oxf, Engl)"},{"key":"675_CR21","volume-title":"E28\u2014impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-na\u00efve patients with active ankylosing spondylitis","year":"2017","unstructured":"Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, et al., editors. E28\u2014impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-na\u00efve patients with active ankylosing spondylitis. Birmingham: British Society for Rheumatology; 2017."},{"issue":"10","key":"675_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103. \n                    https:\/\/doi.org\/10.1001\/jama.2016.12195\n                    \n                  .","journal-title":"JAMA"},{"issue":"4","key":"675_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","volume":"18","author":"A Wailoo","year":"2015","unstructured":"Wailoo A, Hernandez M, Philips C, Brophy S, Siebert S. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Health J Int Soc Pharmacoecon Outcomes Res. 2015;18(4):425\u201331. \n                    https:\/\/doi.org\/10.1016\/j.jval.2015.02.016\n                    \n                  .","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"28","key":"675_CR24","first-page":"1","volume":"11","author":"C McLeod","year":"2007","unstructured":"McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess (Winch, Engl). 2007;11(28):1\u2013158 (iii\u2013iv).","journal-title":"Health Technol Assess (Winch, Engl)"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0675-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0675-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T19:09:40Z","timestamp":1558724980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0675-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0675-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"25 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Marjolijn Van Keep, Steve Beard, Chris Graham and LaStella Miles declare they have no conflicts of interest. Marjolijn Van Keep and Steve Beard are employees of BresMed Health Solutions, and Chris Graham and La Stella Miles are employees of RTI Health Solutions; these organisations were contracted by Novartis Pharmaceuticals UK Ltd to undertake part of the work. Steffen Marc Jugl is an employee of Novartis Pharma AG, Basel, Switzerland, and owns stock and stock options in Novartis Pharma AG, Basel, Switzerland. Praveen Gunda is an employee of Novartis Healthcare Private Limited, Hyderabad, India. Anna Halliday is an employee of Novartis Pharmaceuticals UK Limited, Camberley, UK. Helena Marzo-Ortega has received grants from Janssen and Pfizer, and honoraria for speaking arrangements\/advisory boards from AbbVie, Celgene, Janssen, Eli Lilly & Co, MSD, Novartis, Pfizer and UCB. Paul Emery has undertaken clinical trials and provided expert advice to Pfizer, MSD, AbbVie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Eli Lilly & Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by Novartis Pharmaceuticals UK Ltd, Camberley, UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets used for the cost-effectiveness analysis are not publicly available, but may be available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}